Significant anti-tumor efficacy was observed in 2 models: BCX.066 (Fig. 2A), which had FGFR2 amplification/overexpression; and PDX.007 (Fig. 2B), which had FGFR2 Y375C mutation and FGFR2 amplification. The gene discussed is FGFR2; the disease is neoplasm.